Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?".

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.The New England journal of medicine · 2023
   Trial
2. Sorafenib for Advanced and Refractory Desmoid Tumors.The New England journal of medicine · 2018
   Trial
3. From HPV infection to cervical precancer: Molecular mechanisms, immune microenvironment and emerging technologies.Cellular and molecular life sciences : CMLS · 2026
   Review
4. Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments.Cancers · 2026
   Review
5. Desmoid Tumor of the Porta Hepatis: A Rare Location With Unusual Clinical Presentation.Case reports in hepatology · 2026
   Article
6. Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis.Frontiers in oncology · 2024
   Article
7. Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.NPJ precision oncology · 2022
   Review
8. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.Proceedings of the National Academy of Sciences of the United States of America · 2021
   Article
9. Locally Aggressive Connective Tissue Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
   Review
10. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.Cancer treatment reviews · 2018
    Review
11. Desmoid-Type Fibromatosis: Who, When, and How to Treat.Current treatment options in oncology · 2017
    Review

Corrections and comments

• Comment on
  Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as